Justin F. Gainor, MD, discusses the recent FDA approvals of pralsetinib and selpercatinib, which led to expanded treatment options for patients with non–small cell lung cancer who harbor RET rearrangements.
Ramez N. Eskander, MD, discusses updated data for pembrolizumab plus chemotherapy in patients with advanced/recurrent endometrial cancer.
Health Canada has approved pembrolizumab plus chemotherapy for first-line, locally advanced, unresectable, or metastatic, HER2-negative gastric/GEJ cancer.
The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies.
R. Lor Randall, MD, FACS, discusses the changing field of orthopedic oncology and gives his takeaways from the American Academy of Orthopedic Surgeons Meeting.
A unique approach combining genomic and sensitivity testing with machine learning was feasible for guiding treatment selection in pediatric cancers.
The FDA has approved alectinib as adjuvant treatment in select patients with ALK-positive non–small cell lung cancer.
Matthew S. Johnson, MD, discusses a pilot study of Y-90 radioembolization plus pembrolizumab in patients with poor-prognosis hepatocellular carcinoma.
Idalid Franco, MD, MPH, discusses the integration of immunotherapy, molecular biomarkers, and risk factors for recurrence into the endometrial cancer paradigm.
Tivumecirnon plus pembrolizumab elicited responses in recurrent or metastatic head and neck squamous cell carcinoma after checkpoint inhibitor exposure.
Vikram Narayan, MD, details the mechanism of action of the nadofaragene firadenovec and how the agent is impacting care for patients with BCG-unresponsive non–muscle invasive…
